全球首个糖尿病神经痛贴剂获批 北京经开区企业填补外用药物空白

Core Viewpoint - Beijing Tide Pharmaceutical Co., Ltd. has received approval for its self-developed lidocaine gel patch (Dabain) to be used for the treatment of diabetic peripheral neuropathic pain, making it the first and only approved topical analgesic for this indication globally [1] Group 1: Product Approval and Market Impact - The approval of Dabain fills a treatment gap for first-line medications in China and abroad, potentially providing a safer and more convenient pain management solution for over 200 million diabetic patients in China [1] - Approximately two-thirds of type 2 diabetes patients may develop diabetic peripheral neuropathy, with more than half of these patients progressing to diabetic peripheral neuropathic pain, which significantly affects their quality of life [1] Group 2: Clinical Challenges and Limitations - Diabetic peripheral neuropathic pain is often underdiagnosed and inadequately treated, with common oral medications having significant side effects and addiction potential, particularly impacting elderly and renal impairment patients [1] - The pain associated with this condition can severely disrupt sleep and emotional well-being, leading to anxiety and depression, highlighting the need for effective treatment options [1]